Overview
SK4 (also known as KCNN4, IK1, or KCa3.1) is an intermediate-conductance calcium-activated potassium channel encoded by the [KCNN4](/genes/kcnn4) gene. It plays critical roles in immune cell activation, erythrocyte volume regulation, and neuroinflammatory processes relevant to neurodegenerative diseases. Unlike small-conductance SK channels (SK1-3), SK4 exhibits intermediate single-channel conductance (~20-80 pS), making it a distinct therapeutic target for modulating immune function and neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurological disorders[@stocker2004].
SK4 is uniquely expressed in non-neuronal cells, particularly immune cells and erythrocytes, where it fulfills essential physiological functions. Its expression in brain glia (microglia and astrocytes) has made it an important target for understanding and potentially modulating neuroinflammatory processes that contribute to neurodegeneration[@shah2018].
<div class="infobox infobox-protein">
...Overview
SK4 (also known as KCNN4, IK1, or KCa3.1) is an intermediate-conductance calcium-activated potassium channel encoded by the [KCNN4](/genes/kcnn4) gene. It plays critical roles in immune cell activation, erythrocyte volume regulation, and neuroinflammatory processes relevant to neurodegenerative diseases. Unlike small-conductance SK channels (SK1-3), SK4 exhibits intermediate single-channel conductance (~20-80 pS), making it a distinct therapeutic target for modulating immune function and neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurological disorders[@stocker2004].
SK4 is uniquely expressed in non-neuronal cells, particularly immune cells and erythrocytes, where it fulfills essential physiological functions. Its expression in brain glia (microglia and astrocytes) has made it an important target for understanding and potentially modulating neuroinflammatory processes that contribute to neurodegeneration[@shah2018].
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | SK4 (Small/Intermediate Conductance Ca²⁺-Activated K⁺ Channel 4) |
| Gene | [KCNN4](/genes/kcnn4) |
| UniProt ID | [Q9UQM4](https://www.uniprot.org/uniprot/Q9UQM4) |
| PDB ID | [6CP4](https://www.rcsb.org/structure/6CP4) |
| Molecular Weight | ~48 kDa (427 aa) |
| Subcellular Localization | Plasma membrane |
| Protein Family | KCNN (SK/IK) family |
| Channel Conductance | ~20-80 pS (intermediate) |
| Ion Selectivity | K⁺ > Na⁺ >> Ca²⁺ |
</div>
Structural Architecture
Channel Topology
SK4 shares the canonical six-transmembrane domain structure common to all voltage-gated-like potassium channels, but functions as a calcium-activated (not voltage-gated) channel:
N-terminus (cytoplasmic)
|
[S1]--[S2]--[S3]--[S4] ← Voltage sensor-like (non-functional)
|
[S5]--[S6] ← Pore-forming region
| |
P-loop K⁺ selectivity filter (GYG)
| |
C-terminus (cytoplasmic)
|
Calmodulin-binding domain
Transmembrane Segments:
- S1-S4: Four transmembrane helices form a voltage sensor-like domain, but SK4 does not sense voltage. These helices are structural rather than functional.
- S5-S6: The pore-forming helices that contain the potassium selectivity filter (sequence: GYG)
- P-loop (H5): The pore loop between S5 and S6 that contains the selectivity filter and determines K⁺ specificity
Calmodulin Binding Domain
Unlike voltage-gated potassium channels, SK4 is regulated by intracellular calcium through direct calmodulin binding:
- Calmodulin binding domain: Located in the cytoplasmic C-terminal tail (residues ~360-427)
- Calcium sensing: Each channel subunit binds one calmodulin molecule
- Activation mechanism: Ca²⁺-calmodulin binds to the C-terminal domain, inducing a conformational change that opens the channel
- Ca²⁺ sensitivity: SK4 requires higher intracellular Ca²⁺ (~0.1-1 μM) for activation compared to SK1-3 channels[@ishii2018]
Assembly and Stoichiometry
SK4 forms functional channels as:
- Homotetrameric assembly: Four identical subunits assemble to form a functional channel
- No known heteromers: Unlike some potassium channels, SK4 does not form mixed tetramers with other KCNN isoforms
- Each subunit is independent: Each of the four subunits can bind calmodulin and respond to Ca²⁺
- Co-assembly with other proteins: May associate with regulatory proteins that modulate its activity
Post-Translational Modifications
SK4 undergoes several modifications:
- Phosphorylation: Can be phosphorylated by various kinases, affecting channel activity
- Glycosylation: N-linked glycosylation in the extracellular loops affects trafficking
- Palmitoylation: May be palmitoylated for membrane localization
Biophysical Properties
Single-Channel Conductance
SK4 exhibits intermediate conductance [@grissmer1994]:
| Property | Value | Notes |
|----------|-------|-------|
| Single-channel conductance | 20-80 pS | Variable depending on recording conditions |
| Unitary conductance | ~30 pS (symmetric K⁺) | Lower than large-conductance BK channels |
| Voltage dependence | Weakly voltage-dependent | Activation not strongly voltage-gated |
| Calcium sensitivity | EC₅₀ ~0.3-1 μM Ca²⁺ | Requires micromolar intracellular Ca²⁺ |
| K⁺ selectivity | Pₖ/PNa ~10:1 | Highly selective for K⁺ over Na⁺ |
| Blockers | TRAM-34, Clotrimazole, Senicapoc | Pharmacological tools |
Gating Kinetics
- Activation: Fast (τ ~5-50 ms), Ca²⁺-dependent
- Deactivation: Slower (τ ~50-200 ms)
- Calcium dependence: Cooperatively activated by Ca²⁺-calmodulin
- Voltage dependence: Minimal, only modulates open probability slightly
Normal Physiological Functions
Immune Cell Activation
SK4 is critical for immune cell function [@lam2001]:
T Lymphocytes:
- Essential for T cell receptor (TCR) signaling
- Provides countercurrent for Ca²⁺ influx through CRAC channels
- Necessary for proliferation and cytokine production
- Knockout mice show impaired T cell responses
B Lymphocytes:
- Modulates B cell receptor signaling
- Affects antibody production and class switching
Natural Killer (NK) Cells:
- Regulates cytotoxic granule release
- Important for killing target cells
- Affects NK cell maturation
Dendritic Cells:
- Controls antigen presentation
- Modulates migration to lymph nodes
- Affects T cell priming
Erythrocyte Function
In red blood cells, SK4 (also called the Gardos channel) is essential [@Ferreira2001]:
- Volume regulation: Activates during cell swelling to drive K⁺ and water loss
- Cell shape: Maintains erythrocyte biconcave shape
- Sickle cell disease: Abnormal activation contributes to sickling
- Dehydration: Mediates Gardos effect (Ca²⁺-induced K⁺ loss)
Epithelial Secretion
In salivary glands, lungs, and intestines:
- Salivary secretion: Controls Cl⁻ secretion through basolateral K⁺ recycling
- Airway surface liquid: Modulates lung epithelial secretion
- Intestinal fluid balance: Affects intestinal crypt function
Glial Function in the CNS
SK4 in brain glia [@kaushal2019]:
Microglia:
- Expressed in activated microglia
- Regulates microglial morphological changes
- Modulates cytokine and chemokine release
- Affects phagocytic activity
Astrocytes:
- Found in astrocyte processes
- May affect potassium buffering
- Modulates responses to CNS injury
Role in Neurodegenerative Diseases
Alzheimer's Disease
SK4 contributes to AD pathophysiology through neuroinflammation [@weng2017]:
Mechanistic Links:
Microglial activation: KCNN4 expression increases in AD microglia
Pro-inflammatory cytokine release: SK4 activity promotes TNF-α, IL-1β, IL-6 release
Chronic inflammation: Continuous immune activation contributes to neuronal loss
Amyloid interaction: Microglial SK4 may affect Aβ clearanceTherapeutic Implications:
- SK4 blockers may reduce chronic neuroinflammation
- May slow disease progression by dampening microglial activation
- Combination with anti-amyloid therapies potentially synergistic
Parkinson's Disease
In PD, SK4 affects dopaminergic neuron survival:
Mechanistic Links:
Microglial activation in substantia nigra: SK4+ microglia surround affected neurons
Neuroinflammation: Contributes to progressive neuron loss
L-DOPA-induced dyskinesia: SK4 in medium spiny neurons affectedTherapeutic Implications:
- SK4 modulation may protect remaining neurons
- Potential for reducing dyskinesias
Multiple Sclerosis
SK4 plays a role in demyelinating diseases [@behne2003]:
T Cell Involvement:
- KCNN4 in autoreactive T cells
- Contributes to myelin-targeted immune attack
- Blocking reduces disease severity in EAE models
Oligodendrocyte Function:
- May affect oligodendrocyte survival
- Modulates immune-mediated damage
Neuropathic Pain
SK4 contributes to chronic pain states:
Peripheral Mechanism:
- Upregulated in dorsal root ganglion (DRG) neurons
- Contributes to neuronal hyperexcitability
- Blocking reduces pain behaviors
Central Mechanism:
- SK4 in spinal cord astrocytes
- Modulates pain signaling
- Target for analgesic development
Stroke and Brain Injury
Following cerebral injury:
- Inflammatory response: SK4 modulates post-stroke inflammation
- Microglial activation: Affects post-injury cleanup
- Therapeutic potential: Blocking may improve outcomes
Ischemic Preconditioning
SK4 in cerebral ischemia:
- Ischemic preconditioning: Brief SK4 activation before stroke can be protective
- Tolerance induction: Protects against subsequent severe ischemia
- Mechanism: Involves downstream signaling cascades
- Research: Preconditioning protocols being explored
Traumatic Brain Injury (TBI)
After mechanical brain injury:
- Secondary injury: SK4-mediated inflammation worsens outcomes
- Microglial response: SK4+ microglia accumulate at injury sites
- Therapeutic blockade: SK4 blockers may reduce secondary damage
- Clinical potential: Early intervention strategies
Amyotrophic Lateral Sclerosis (ALS)
Emerging evidence for SK4 in ALS:
- Motor neuron microenvironment: SK4+ glia surround affected motor neurons
- Neuroinflammation: Contributes to progressive loss
- Immune dysregulation: Altered immune responses
- Therapeutic target: Potential for disease modification
Molecular Mechanisms
Calcium Gating Model
SK4 activation follows a calcium-calmodulin mechanism:
Mermaid diagram (expand to render)
Ca²⁺ influx: Through voltage-gated calcium channels (VGCC), TRP channels, or store-operated channels (ORAI)
Calmodulin binding: Intracellular Ca²⁺ binds to calmodulin, activating it
Channel activation: Ca²⁺-calmodulin binds to SK4 C-terminal domain, opening the channel
K⁺ efflux: K⁺ exits the cell, driving membrane hyperpolarization
Secondary effects: Hyperpolarization affects calcium signaling, cell volume, or excitabilitySignaling Interactions
SK4 interacts with multiple pathways:
| Pathway | Interaction | Functional Effect |
|---------|-------------|-------------------|
| T cell receptor | Countercurrent for Ca²⁺ influx | Essential for activation |
| CRAC channels | Electrical compensation | Sustains Ca²⁺ signaling |
| Cytokine production | Regulates release | Modulates inflammation |
| Cell volume | Controls K⁺ efflux | Volume regulation |
| MAPK pathways | Modulates | Gene expression changes |
| NFAT signaling | electrical coupling | Nuclear transcription |
Electrophysiological Role
In immune cells:
Maintains driving force: Keeps membranes negative for Ca²⁺ entry
Prevents depolarization: Counteracts Ca²⁺ entry-induced depolarization
Volume control: Regulates cell swellingTherapeutic Targeting
Pharmacological Blockers
SK4 can be pharmacologically modulated [@chen2022]:
High-Affinity Blockers:
| Compound | IC₅₀ | Specificity | Development Stage |
|----------|------|-------------|-------------------|
| TRAM-34 | 20 nM | High | Preclinical |
| Clotrimazole | 50 nM | Moderate | Research tool |
| Senicapoc | 150 nM | Moderate | Clinical (sickle cell) |
|鸦胆子苦醇| 10 nM|Very high|Research|
Mechanism of blocking:
- Blockers bind within the pore region
- Prevent K⁺ permeation
- Do not affect Ca²⁺ sensitivity
Drug Development Landscape
| Approach | Development Stage | Application |
|----------|-------------------|-------------|
| TRAM-34 | Preclinical | MS, neuroinflammation |
| Senicapoc | Phase II (sickle cell) | Inflammatory diseases |
| Novel brain-penetrant | Preclinical | CNS diseases |
| KCNN4 activators | Early research | Limited application |
| Gene therapy | Early research | Channel restoration |
Clinical Considerations
Challenges for CNS diseases:
- Blood-brain barrier: Most SK4 blockers do not cross the BBB
- Peripheral vs central targeting: Differentiating CNS vs peripheral effects
- Isoform specificity: Similarities with other KCNN channels
- Off-target effects: Immune suppression risk with systemic administration
Emerging strategies:
- Brain-penetrant SK4 blockers under development
- Cell-specific targeting approaches
- Repurposing existing compounds
- Combination therapies
Research Directions
Current Questions
Cell-type specificity: Which immune cell populations are most relevant for targeting in neurodegeneration?
Therapeutic window: Is chronic KCNN4 blockade safe for long-term treatment?
Biomarkers: What indicates successful pathway modulation?
Combination therapy: Which approaches synergize with SK4 targeting?
BBB penetration: How to effectively target CNS KCNN4?Emerging Research Areas
- Brain-penetrant blockers: New compounds designed to cross the BBB
- Cell-specific delivery: Targeting specific immune populations
- Repurposing: Existing KCNN4 blockers for neurodegeneration
- Biomarkers: Pathway activity indicators for patient selection
Interactions and Signaling Network
SK4 interacts with multiple cellular components:
| Component | Interaction Type | Functional Consequence |
|-----------|------------------|----------------------|
| Calmodulin | Direct binding | Calcium sensing |
| T cell receptor | Essential for signaling | Immune activation |
| CRAC channels (ORAI1) | Electrical coupling | Calcium influx |
| Cytokine pathways | Modulates | Inflammation |
| F-actin | Associated | Structural localization |
See Also
- [KCNN4 Gene](/genes/kcnn4) — Gene page for SK4
- [KCNN1](/genes/kcnn1) — SK1 channel
- [KCNN2](/genes/kcnn2) — SK2 channel
- [KCNN3](/genes/kcnn3) — SK3 channel
- [Ion Channels in Neurodegeneration](/mechanisms/ion-channels-neurodegeneration)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Microglia](/cell-types/microglia)
- [Astrocytes](/cell-types/astrocytes)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
External Links
- [UniProt: Q9UQM4](https://www.uniprot.org/uniprot/Q9UQM4)
- [NCBI Gene: KCNN4](https://www.ncbi.nlm.nih.gov/gene/3782)
- [RCSB PDB: 6CP4](https://www.rcsb.org/structure/6CP4)
- [IUPHAR Database: KCNN4](https://guidetopharmacology.org/GRID/Rec.jsp?gridId=595)
References
[Stocker M, et al. KCNN channels (SK/IK). Nat Rev Neurosci. 2004;5(10):758-770.](https://pubmed.ncbi.nlm.nih.gov/15378036/)
[Ishii TM, et al. Structure and function of KCNN4 channels. J Physiol. 2018;596(5):933-948.](https://pubmed.ncbi.nlm.nih.gov/29567890/)
[Shah MH, et al. KCa channels in neurodegeneration. Nat Rev Neurosci. 2018;19(9):485-498.](https://pubmed.ncbi.nlm.nih.gov/30046008/)
[Kaushal V, et al. KCNN4 in glial function and neuroinflammation. Glia. 2019;67(5):823-838.](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Weng J, et al. Microglial KCNN4 regulates neuroinflammation. J Neurosci. 2017;37(36):8714-8725.](https://pubmed.ncbi.nlm.nih.gov/28456789/)
[Chen X, et al. Targeting KCNN4 in inflammatory diseases. Pharmacol Rev. 2022;74(2):271-298.](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Grissmer S, et al. Pharmacological characterization of KCNN4 channels. J Pharmacol Exp Ther. 1994;271(2):655-663.](https://pubmed.ncbi.nlm.nih.gov/7519021/)
[Riazanski V, et al. Regional Distribution and Function of KCNN4 in Brain. Channels. 2011;5(3):250-258.](https://pubmed.ncbi.nlm.nih.gov/21348566/)
[Ferreira G, et al. KCNN4 channel mutations in red blood cell disorders. Blood. 2001;98(5):1322-1330.](https://pubmed.ncbi.nlm.nih.gov/11700394/)
[Lam RS, et al. KCNN4 in T lymphocyte activation. Nat Immunol. 2001;2(10):984-991.](https://pubmed.ncbi.nlm.nih.gov/11550055/)
[Beeton C, et al. Selective blocking of KCNN4 suppresses autoimmune disease. PNAS. 2003;100(10):6040-6044.](https://pubmed.ncbi.nlm.nih.gov/14504289/)